A Phase I clinical trial of AT101, a new CAR T cell therapy targeting CD19 through a distinct binding mechanism, has shown a 100% complete response rate in patients with relapsed or refractory B cell non-Hodgkin's lymphoma. The treatment was found to be safe with manageable side effects and is expected to build upon the effectiveness o...
Researchers at University of Cincinnati Cancer Center present Phase 2 clinical trial results for a new BTK inhibitor treatment that offers potential for improved efficacy and safety in chronic lymphocytic leukemia. The study also explores the use of IRAK4 inhibitors to target acute myeloid leukemia cells, with promising results.
Researchers from the Mass General Cancer Center presented studies on psychiatric and substance use disorders as independent predictors of treatment response and outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia (AML) treated with Venetoclax Combinations. Additionally, a Phase 1 Study of CAR-T-ddBCMA for the...
A joint research team from South Korea and the US has developed a new genetic classification system for gastric cancer, identifying six consensual genomic subtypes (CGSs) with distinct characteristics. The study suggests potential treatments for each subtype, including immunotherapy and targeted therapies.
A five-year, $6.15-million NIH grant has enabled six North Carolina institutions to collaborate on advancing the science of nephrology, hematology, and urology. The NC KUH TRIO Program aims to train the next generation of researchers and foster academic and professional development across disciplines and institutions.
Researchers developed a new technique, GoT-Splice, to analyze RNA splicing in individual cells, revealing how mutations in genes controlling this process lead to diseases. The study linked these mutations to specific changes in immature red blood cells and discovered disruptions in the gene BAX.
A study published in Blood journal found that children with diverse gut microbiota before stem cell transplant had significantly better overall patient survival and fewer complications. Higher microbiota diversity was also associated with lower risk of acute graft-versus-host disease.
Researchers have discovered a link between adenovirus infection and an anti-platelet factor 4 disorder, which can cause severe thrombocytopenia. The condition is rare and potentially fatal, and has been reported in patients with viral symptoms and no exposure to heparin or vaccines.
A new study highlights the difficulty in diagnosing blood disorders like myelodysplastic syndromes/neoplasms (MDS), which can lead to treatment mistakes. The researchers found that expert pathologists disagreed with local pathologists' diagnoses in about 20% of cases, leading to wrong initial treatments for patients.
Researchers found that checkpoint inhibitors are not effective in treating relapsed aggressive lymphomas after CAR T therapy. The study involved 96 patients from 15 centers and showed only 19% response to checkpoint inhibitor therapy.
Children with acute lymphoblastic leukemia (ALL) who live in extreme poverty are at a significantly higher risk of relapse and have difficulty adhering to treatment. The study highlights the need for clinicians and researchers to assess financial hardship and adherence to treatment to improve outcomes.
Researchers used prime editing to correct the mutation that causes sickle cell disease, restoring normal blood parameters in mice. The approach showed promising results with up to 41% conversion of mutated cells to healthy ones.
A study published in the Journal of Infection found that mNGS was significantly more effective at detecting bloodstream infections than conventional microbiological tests (CMTs), identifying 187 infection cases compared to CMTs' 81. Viral infections were the most common type, with CMV being the leading cause.
Researchers found encouraging responses with revumenib for advanced acute leukemias with KMT2A rearrangements or NPM1 mutations. The overall response rate was 53%, with 78% of patients achieving clearance of measurable residual disease.
A new study found that massage therapy significantly reduces pain, stress, and anxiety in children, adolescents, and young adults with cancer or sickle cell disease. The study published in Pediatric Blood & Cancer reports clinically significant benefits from massage therapy, highlighting its potential as a non-pharmacologic treatment o...
Researchers at WashU Medicine identified a key transition point in the shift from chronic to aggressive leukemia, where blocking a molecule called DUSP6 prevents disease progression. Inhibiting this molecule also reduces inflammation in models of the disease.
Modakafusp alfa has shown significant potential in combating multiple myeloma with 43% of patients experiencing a partial response. The treatment targets interferon in cells expressing CD38, a marker present on myeloma cells and immune cells.
Researchers have demonstrated successful re-treatment with CAR T cell therapy for patients whose cancers relapsed after previous treatment. The novel fourth-generation CAR T therapy, huCART19-IL18, showed safe and potent antitumor efficacy in a Phase I clinical trial.
The National Institutes of Health has awarded Albert Einstein College of Medicine a five-year, $6.6 million grant to train young scientists in kidney, urology, and hematology research. The New York Consortium for Interdisciplinary Training in Kidney, Urological, and Hematological Research will bring together experts from four medical s...
A study by Cincinnati Children's Hospital Medical Center has identified two genes, ZEB1 and ALDH1A1, as critical in producing malignant cells in MPNST. The research found that disrupting these genes can slow tumor growth and reduce proliferation in mice, suggesting potential new treatments for the disease.
A team of researchers at Baylor College of Medicine has investigated how breast cancer cells lose their ER expression, revealing a mechanism that explains the process and offers possibilities to overcome it. The study found that over-expressing 14-3-3τ in cancer cells leads to ER loss, with other molecular players such as AKT and GATA3...
This study found that glycolysis is critical for T cell activation in acute graft-versus-host disease. GCs combined with glycolysis inhibitors cooperatively abrogate acute graft-versus-host disease.
Researchers found a direct connection between low oxygen conditions and increased fetal hemoglobin production in adults. A drug that activates the cellular response to low oxygen could potentially treat sickle cell disease by promoting HbF production, which has therapeutic benefits.
Researchers outline a five-step approach to increase racial representation in cancer clinical trials through DRIVE: Diversity officer, Ranking of clinical studies, Individual diversity plan, Verification, and Training. This can lead to more inclusive and individualized treatment for diverse patient populations.
A new set of guidelines aims to increase patient diversity in lung cancer clinical trials by relaxing eligibility requirements. The recommendations, published in JAMA Oncology, suggest that patients with prior or concurrent cancers, brain metastases, and mild liver impairment can be included in trials.
The University of Cincinnati is conducting a study on a potential new treatment for pancreatic cancer using SapC-DOPG, a nanotechnology drug delivery system. The treatment has shown promise in reducing tumor growth by 50-80% in animal models and aims to develop an effective immunotherapy treatment.
A recent study published in Blood Advances found a significant disparity in the representation of women among medical educators, with women comprising just 37.7% of speakers at hematology and medical oncology board review lectures. The study also highlights the importance of increasing diversity in educational opportunities to promote ...
A new study published in Blood Advances found that virtual frailty assessments are both safe and feasible when conducted virtually. The study evaluated 185 patients with blood cancers who completed a virtual assessment, finding that 81.1% successfully completed the test without falls or safety events.
Pediatric pathologists have discovered a new, aggressive subtype of liver cancer in children, characterized by molecular features that don't fit existing classification models. The tumors are less responsive to chemotherapy and have poor outcomes, prompting the development of a diagnostic algorithm to guide specialized treatment.
A study by Weill Cornell Medicine investigators has revealed the cause and potential precision therapies for a type of aggressive blood cancer called diffuse large B cell lymphoma (DLBCL). The research found that SETD2 gene mutations can lead to an accumulation of DNA damage, causing cancer cells to grow uncontrollably.
Research led by Adam Green, MD, shows that the youngest patients with brain tumors (ages 0-3 months) have about half the five-year survival rate as children ages 1-19. The study analyzed population-based data for almost 14,500 children and found significantly poorer outcomes among the youngest patients.
A comprehensive review of over 60 studies confirms that COVID vaccination is around 80% effective in protecting people with cancer against SARS-CoV-2 infection. The mRNA vaccines were found to be the most effective, and multiple vaccinations are recommended for better protection.
A new study has found that World Trade Center responders have an increased mutational burden, elevating their risk for blood cancers and cardiovascular disease. The researchers compared DNA samples from 203 Nashville firefighters to a control group of 52 firefighters who were not exposed to particulate matter at the disaster.
The NRG-RTOG 1010 clinical trial found that adding trastuzumab to chemoradiation and surgery did not improve disease-free survival for HER2-positive esophageal adenocarcinoma patients. Despite this, the study highlights future research opportunities to explore combining trastuzumab with other HER2-targeting agents.
A study from Weill Cornell Medicine and Cornell University reveals that targeting protein ATF4 and its related metabolic protein SIRT3 can trick lymphoma cells into starving themselves, slowing their growth.
A new study published in the New England Journal of Medicine found that using CAR T therapy as a second-line treatment provided better outcomes compared to standard care in patients with diffuse large B-cell lymphoma. The two-year follow-up data showed a median event-free survival of 8.3 months in the CAR T arm versus 2 months in the s...
Researchers at the University of Texas MD Anderson Cancer Center demonstrated axi-cel's efficacy in treating high-risk lymphoma patients with enhanced responses and prolonged survival benefits. The study showed improved outcomes for patients with indolent non-Hodgkin lymphoma, with an estimated 81% overall survival rate at 24 months.
Recent research reveals that endothelial cells produce all necessary coagulation proteins for thrombin generation, enabling the clotting process to occur on their surfaces. This finding shifts our understanding of blood clot development and treatment strategies.
A new protein variant called CLIP-170S allows cancer cells to dodge chemotherapy drugs, rendering them ineffective. Researchers discovered this variant in more than 60% of patients with gastric cancer and are exploring a combination therapy involving imatinib to overcome resistance.
A novel gene therapy has shown sustained expression of clotting factor VIII, leading to a reduction or complete elimination of bleeding events in patients with hemophilia A. The trial demonstrated improved production of coagulation factor VIII over prolonged periods.
People with blood cancers are at higher risk of severe COVID-19 illness; research suggests they don't always achieve optimal protection from vaccination. A new study found that patients with lymphoma were more likely to develop post-vaccination COVID-19 infection compared to those with other blood cancers.
Researchers at UC Davis Comprehensive Cancer Center are investigating whether turmeric can successfully reduce joint pain in breast cancer patients and improve their quality of life. The study aims to provide important data on the safety and effectiveness of using turmeric with oral anti-estrogen therapy.
Two studies by CU Cancer Center researchers found that chronic inflammation can serve as a key factor in the development of leukemia. Chronic inflammation reduces the fitness of normal cells, hindering their ability to reproduce and creating space for cancer-causing mutations to proliferate. The findings support the theory of adaptive ...
St. Jude Children's Research Hospital scientists have developed an integrated system to better understand and possibly manipulate gene expression for treatment of disorders like sickle cell disease and beta thalassemia. The new method identified dozens of DNA regulatory elements that orchestrate fetal-to-adult hemoglobin switch, offeri...
A new set of guidelines developed by AATS and ESTS recommends a 30-day course of Venous Thromboembolism (VTE) prophylaxis post-discharge for patients undergoing surgical resection for lung or esophagus cancer. The guideline panel endorsed by American Society of Hematology and International Society on Thrombosis and Haemostasis found th...
Researchers developed an AI-powered imaging-based tool to estimate hemoglobin levels using a microfluidic chip and automated microscope. The system was validated with a high correlation coefficient of 0.99, meeting regulatory standards. This innovation could revolutionize medical diagnostics by reducing costs and laboratory footprint.
Researchers found extremely low detection of SARS-CoV-2 on environmental surfaces in outpatient and inpatient oncology areas, including a COVID-19 floor. The study's results confirm the effectiveness of enhanced cleaning and disinfecting policies in reducing virus transmission.
A significant number of NHL patients achieved complete remission and progression-free survival with Kymriah, a personalized cellular therapy. The study demonstrated the durability of this approach, with most patients remaining in remission five years after treatment.
The American Society of Hematology, International Society on Thrombosis and Haemostasis, National Hemophilia Foundation, and World Federation of Hemophilia have developed joint clinical practice guidelines for von Willebrand Disease (VWD). The guidelines provide recommendations for diagnosis and management, including the use of injecta...
A new toolkit aims to harmonize data collection of blood clotting events associated with COVID-19, enabling better comparison of findings across trials. The toolkit provides a customizable set of variables to collect high-quality data on thrombosis-related endpoints, standardizing definitions and measurement tools.
Researchers at Cleveland Clinic's Taussig Cancer Institute have identified a potential new class of targeted drugs to treat myeloid leukemias, including those with the common TET2 gene mutation. The new pharmacological strategy, TETi76, preferentially targets and eliminates leukemia cells with TET2 mutations in preclinical models.
Researchers have discovered that isatuximab, a monoclonal antibody approved for multiple myeloma, can effectively treat relapsed refractory AL amyloidosis. The study showed an overall response rate of 77% among patients who received the treatment.
New research suggests that testing for tumor DNA in DLBCL patients' stem cells or blood can help predict relapse risk. Patients with positive results may benefit from alternative treatments like CAR T cell therapy and prompt interventions to prevent relapse.
Researchers have found that knocking out the CD5 gene on CAR T cells using CRISPR-Cas9 technology enhances their ability to eliminate blood cancers. Mice infused with CD5-deleted CAR T cells showed higher T cell proliferation and reduced tumor size compared to non-edited cells.
A subcutaneous injection of teclistamab elicits responses in 74% of patients with relapsed/refractory multiple myeloma, offering a promising treatment option for patients with poor prognoses. The study's results suggest that teclistamab takes a similar approach to cellular therapies but is more convenient and faster to administer.
Axicabtagene ciloleucel (axi-cel) achieved undetectable cancer levels in nearly 80% of patients, and durable responses in most participants. The therapy demonstrated improved response rates for follicular lymphoma compared to marginal zone lymphoma.
The combination of venetoclax with chemotherapy improves outcomes for patients with AML and MDS, with a promising overall response rate and acceptable safety profile. Venetoclax also demonstrates efficacy in treating high-risk MDS when combined with azacitidine.
A recent study by Dana-Farber Cancer Institute scientists has found that clonal hematopoiesis can confer a health benefit in the setting of allogeneic stem cell or bone marrow transplants. Patients who received transplants from older donors with CH had a lower risk of relapse and longer survival compared to those without CH.
A new clinical trial has found that donor stem cell transplantation nearly doubles the survival rate of older patients with higher-risk myelodysplastic syndrome (MDS), aged 50-75. The study suggests that transplant should be considered for all eligible patients, ideally referred early to increase chances of finding a suitable donor.
Researchers evaluated the efficacy and safety of fibryga, Octaplas, and Octaplex in treating congenital and acquired bleeding disorders. Fibryga demonstrated efficacy in on-demand treatment and perioperative prophylaxis for patients with rare congenital fibrinogen deficiency.